As Pharmacy Technician Day approaches, the CEO of the Pharmacy Technician Certification Board argues that real recognition means career ladders, consistent scope regulations, and investment in certification.
|Articles|June 1, 2006
- Volume 0 0
FDA PANEL OKs CERVICAL CANCER VACCINE
Advertisement
Merck's Gardasil, a vaccine that blocksviruses that cause most cervical cancers,has been given the green light by an FDAadvisory committee. The panel voted 13 to 0,stating that the vaccine was safe and effectiveand should be approved.The FDA, whichusually follows the panel's recommendation,is expected to make a decision this month.
The vaccine is indicated for the treatmentof sexually transmitted diseases, particularly4 strains of human papillomavirus thatcan cause cervical cancer and genital warts.A Merck official said that the vaccine couldbe recommended for women aged 9 to 26,but it would work best for individuals whohave not yet had sex. The expected cost ofthe vaccine is $300 to $500 (for 3 injectionsgiven over 6 months).
Articles in this issue
over 20 years ago
can you READ these Rxs?over 20 years ago
case STUDIESover 20 years ago
Compounding HOTLINEover 20 years ago
RESPy AWARDover 20 years ago
Compounding for Prenatal Patientsover 20 years ago
Prescription Monitoring Programsover 20 years ago
Patients Sue the US Government to Allow Drugs from Canadaover 20 years ago
FMEA Can Help Prevent Errorsover 20 years ago
On-line Health Care: Identifying Quality InformationAdvertisement
Related to this article
William J. Peppard, PharmD, explains how emerging suzetrigine findings after knee arthroplasty connect opioid stewardship with functional recovery and the pharmacist’s role in ensuring treatment access.
Tor Härnqvist, MD, discusses immune testing after invasive pneumococcal disease, serotype-informed vaccine selection, and pharmacists' role in supporting patients on immunoglobulin therapy.
In adults with type 2 diabetes at high cardiovascular (CV) risk, the oral GLP-1 RA also improved HbA1C and weight, with less hypoglycemia but more GI events.
In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.
BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1C by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Butter, Beef Tallow, and LDL: Where Dietary Guidelines Diverge
2
Pharmacists Key to Lp(a) Counseling and Lipid Optimization
3
Precision in Practice: Biomarker Testing and Treatment Selection in Primary Advanced or Recurrent Endometrial Cancer
4
Why Patients Fear Statins Will Affect Their Memory
5